2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Revenue | $493M | $529M | $571M | $598M | $590M |
Cost of Revenue | $276M | $286M | $306M | $303M | $288M |
Gross Profit | $217M | $243M | $265M | $295M | $301M |
Gross Profit % | 44% | 46% | 46% | 49% | 51% |
R&D Expenses | $7.3M | $7.4M | $7.3M | $9M | $0 |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Net Income | $5.6M | $40M | $20M | $54M | $82M |
Dep. & Amort. | $21M | $22M | $20M | $16M | $13M |
Def. Tax | -$7.8M | $9.6M | -$5.3M | $460K | $435K |
Stock Comp. | $9.6M | $9.2M | $14M | $8.6M | $11M |
Chg. in WC | -$11M | -$23M | -$12M | $2.5M | -$24M |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Cash | $152M | $140M | $121M | $154M | $167M |
ST Investments | $0 | $0 | $0 | $0 | $0 |
Cash & ST Inv. | $152M | $140M | $121M | $154M | $167M |
Receivables | $84M | $103M | $107M | $98M | $104M |
Inventory | $69M | $75M | $84M | $75M | $73M |
Organic sales grew 5% year over year, with EBITDA margins at 23.2% (down slightly due to mix), and full-year fiscal 2025 guidance maintained.
Strong performance in heavy lifting technology (HLT), especially in the U.S. and Europe, contributed to product sales growth; Cortland Biomedical segment grew 33% due to recovery from prior shipment delays.
Gross profit margin declined 110 basis points to 50.5% due to mix shift toward HLT and service projects; initiatives are underway to improve service margins.
E-commerce revenue grew 43% year over year in Q2 and 36% for the first half of fiscal 2025, with recent digital advertising driving significant web traffic growth in the UK and Australia.
Management expects higher revenue and improved EBITDA margins in the second half of fiscal 2025, with Q4 typically being the strongest; M&A pipeline remains robust, focusing on complementary businesses like the recent DTA acquisition.